A UK drug watchdog is calling for warning statements on echinacea products because the ingredient may carry a low risk of allergic reactions in children under 12.
The United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) is enlisting a warning statement for echinacea because it may carry a low risk of allergic reactions in children less than 12 years of age.
The MHRA is a government agency responsible for regulating medicines and medical devices. It’s warning is precautionary, as the agency says parents should not be concerned if they previously gave echinacea to a child under 12.
“This is not a serious safety issue, but parents and carers need to be aware that children under 12 could have a low risk of developing allergic reactions, such as rashes from oral Echinacea products,” said MHRA head of herbal policy, Richard Woodfield. “The MHRA is working with the herbal sector to ensure that all oral Echinacea products are relabeled with a warning that they should not be given to children under 12.”
Children over 12 and adults can continue to use Echinacea, says the MHRA, because the threats of allergy and colds are lower in these populations.
NutriSciences Innovations announces acquisition of XSTO Solutions
October 22nd 2024According to the company’s press release, the strategic acquisition adds six new branded products to the NutriScience portfolio, strengthening its role as a preferred ingredient supplier to leading brands in the wellness, food, and beverage industries.
The Nutritional Outlook Podcast Episode 34: Demystifying Prebiotics and Postbiotics
September 30th 2024In this episode of the Nutritional Outlook Podcast we are looking back on a webcast Nutritional Outlook hosted in May, called “Demystifying the Prebiotic and Postbiotic Markets.” During that event, Sandra Saville, director of education and communication for the International Probiotics Association and Dr. Jessica A. Younes, scientific director of the International Probiotics Association debunked myths about prebiotic and postbiotics, and defined the respective categories to help manufacturers better understand how to responsibly formulate and market prebiotic and postbiotic products.
Balchem’s Newest Launch Optifolin⁺® Brings Innovation to the Folate Market
September 19th 2024Supplement launches featuring 5-MTHF are on the rise with double digit growth. In this episode of Nutritional Outlook’s podcast, we explore Optifolin⁺, a new ingredient in the market that offers essential nutrition from prenatal through adulthood. Join us as we uncover the potential impact of the next evolution in folate, setting the stage for a healthier future.